Investors & Media
Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018
Live Webcast to Begin at
The R&D Day will feature presentations by the following clinicians:
Sally-Anne Hulton, M.D., Consultant Paediatric Nephrologist, Birmingham Women’s and Children’s, U.K., will provide an overview of all forms of primary hyperoxaluria (PH), including epidemiology, symptoms and manifestations, and treatment options. Jules Dienstag, M.D., Physician, Gastrointestinal Unit, Massachusetts General Hospitaland the Carl W. Walter Professor of Medicine, will provide an overview of the Hepatitis B Virus (HBV) infection, including epidemiology, disease progression, and treatment options.
Dicerna’s management team will discuss the Company’s most advanced GalXC programs and future technology directions. Topics will include:
- DCR-PHXC, in development for all forms of PH, which is currently completing a Phase 1 clinical trial with a Phase 2/3 registration trial planned to begin in Q1 2019;
DCR-HBVS, in development for chronic HBV, which is expected to begin
clinical trials in early 2019. Dicerna filed a Clinical Trial
New Zealandin Q4 2018 and expects to file additional regulatory clearances in other countries;
- Recent licensing and collaboration agreements and Dicerna’s business strategy; and
- Advancements to the Company’s GalXC technology platform.
A live webcast of the Dicerna R&D Day and the full presentation will be